ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing

6 days ago

ANN ARBOR, Mich., Sept. 13, 2024 ( GLOBE NEWSWIRE ) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that it has secured $65M in Series D financing.

Ticker	Sentiment	Impact
JNJ	Somewhat Bullish	6 %